Related Experiment Video
Updated: Aug 2, 2025
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.9K
DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for
Bouchra Tawk1,2,3,4, Katrin Rein1,2,3,4, Christian Schwager1,2,3,4
1German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK), Core Center Heidelberg, Germany.
Summary
A new DNA methylation classifier (Hypoxia-M) effectively predicts tumor hypoxia and identifies high-risk head and neck squamous cell carcinoma (HNSCC) patients, improving prognostic accuracy for treatment resistance.
Area of Science:
- Oncology
- Epigenetics
- Genomics
Background:
- Tumor hypoxia is a key factor in head and neck squamous cell carcinoma (HNSCC) treatment resistance.
- Current hypoxia classifiers lack reliability, hindering personalized treatment strategies.
- Epigenetic reprogramming via DNA methylation may reflect chronic hypoxia in tumors.
Purpose of the Study:
- To develop and validate a DNA methylome-based classifier for predicting tumor hypoxia in HNSCC.
- To assess the prognostic value of this classifier in HNSCC patients undergoing radiochemotherapy.
Main Methods:
- Trained a DNA methylation-based hypoxia classifier (Hypoxia-M) using TCGA-HNSCC data and gene expression-based hypoxia signatures (Hypoxia-GES).
- Validated Hypoxia-M in a multicenter trial of HPV-negative HNSCC patients treated with radiochemotherapy (RCHT).
- Evaluated Hypoxia-M's association with local recurrence, overall survival, distant metastasis, and CD8 T-cell infiltration.
Main Results:
- Hypoxia-M, unlike Hypoxia-GES, independently predicted local recurrence and overall survival in both HNSCC cohorts.
- Hypoxia-M showed prognostic value in the TCGA-PanCancer cohort, indicating broad applicability.
- Hypoxia-M status correlated inversely with CD8 T-cell infiltration, suggesting an impact on the tumor immune microenvironment.
Conclusions:
- DNA methylation classifiers represent a novel biomarker approach for assessing tumoral hypoxia in HNSCC.
- Hypoxia-M can identify patients with high-risk features, potentially guiding stratified therapy.
- This epigenetic approach offers a promising tool for improving prognostication and treatment selection in HNSCC.
